NASDAQ:INCY - Incyte Corporation
$81.71
 $1.17
+1.45%
4:00PM EDT
2019-07-22
Incyte Corporation, incorporated on April 8, 1991, is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics. The Company's portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). The Company has initiated REACH1, a pivotal Phase II trial in steroid-refractory acute graft-versus-host-disease (GVHD) and the first in a registration program for ruxolitinib in GVHD. A proof-of-concept trial of itacitinib, a selective janus associated kinases 1 (JAK1) inhibitor, is ongoing for the treatment of patients with acute GVHD.The Company has a portfolio of selective JAK1 inhibitors, including itacitinib and INCB52793. INCB52793 is in a Phase I/II trial in patients with advanced malignancies. INCB54828 is an inhibitor of the Fibroblast Growth Factor Receptor (FGFR) isoforms 1, 2 and 3. The Company is studying its bromodomain (BRD) inhibitors, INCB54329 and INCB57643, in open-label dose-escalation trials in patients with advanced malignancies. INCB53914 is a pan-PIM kinase inhibitor. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  INCY     avg for
industry  
  avg for
sector  
42 stocks weight:  269. 39   0. 00   0. 00  
42 stocks rank:  253. 00   1. 35 K 799. 74  
# analyst opinions:  14. 00   12. 76   13. 14  
mean recommendation:  2. 40   2. 11   2. 07  

quick ratio:  5. 01   5. 61   1. 85  
current ratio:  5. 22   6. 00   2. 31  

target price low:  75. 00   75. 88   108. 31  
target price avg:  88. 07   97. 27   130. 10  
target price high:  113. 00   124. 58   149. 02  
1-yr high:  88. 70   104. 89   135. 09  
last close:  81. 71   79. 79   118. 76  
50-day avg:  81. 15   79. 39   116. 18  
200-day avg:  76. 05   81. 61   114. 52  
1-yr low:  58. 50   62. 76   94. 70  
volume:  616. 94 K 2. 99 M 4. 43 M
50-day avg volume:  1. 17 M 3. 39 M 4. 22 M
200-day avg volume:  1. 43 M 3. 13 M 4. 83 M

1-day return:  1. 45 % 0. 33 % 0. 14 %
this week return:  1. 45 % 0. 33 % 0. 14 %
12-wk return:  -1. 63 % 1. 00 % 3. 51 %
52-wk return:  14. 43 % 0. 58 % 10. 25 %

enterprise value (EV):  15. 67 B 44. 78 B 115. 63 B
market cap:  17. 52 B 38. 01 B 103. 29 B
EBITDA:  350. 37 M 4. 47 B 7. 73 B
enterprise multiple (EV/EBITDA):  44. 71   2. 11   11. 26  
enterprise/revenue (EV/R):  7. 84   61. 53   10. 40  
total revenue:  2. 00 B 10. 43 B 31. 15 B
total debt:  42. 06 M 11. 72 B 16. 76 B
debt/equity:  2. 02   61. 22   124. 43  
net income (common):  252. 94 M 2. 06 B 3. 79 B

shares outstanding:  214. 26 M 562. 08 M 1. 27 B
shares:  180. 87 M 573. 33 M 1. 26 B
shares short:  6. 55 M 11. 60 M 12. 29 M
shares short prior month:  7. 01 M 9. 81 M 12. 46 M
short ratio:  4. 88   5. 88   3. 41  
short % of float:  3. 66 % 6. 88 % 2. 72 %
total cash/share:  7. 37   10. 62   8. 83  
total cash:  1. 58 B 6. 17 B 5. 72 B
free cash flow:  271. 50 M 3. 08 B 3. 10 B
operating cash flow:  471. 05 M 3. 99 B 4. 08 B

book value:  9. 73   12. 74   26. 25  
price/book:  8. 40   4. 38   9. 01  
gross profits:  589. 80 M 7. 93 B 35. 64 B
operating margins:  14. 82 % -319. 65 % -29. 05 %
EBITDA margins:  17. 54 % 11. 82 % 24. 13 %
profit margins:  12. 66 % 5. 62 % 14. 29 %
gross margins:  36. 72 % 34. 75 % 57. 07 %

1-yr max volatility:  7. 03 % --- ---
1-yr mean volatility:  1. 68 % 1. 95 % 1. 25 %

1-yr EPS:  1. 16   1. 58   3. 82  
forward EPS:  2. 91   3. 16   6. 65  
P/E:  70. 32   0. 21   31. 97  
forward P/E:  27. 94   4. 95   15. 14  
PE/G:  2. 33   0. 74   0. 13  
growth:  30. 20 % 295. 81 % 85. 47 %
earnings high:  0. 65   0. 84   1. 56  
earnings avg:  0. 49   0. 65   1. 45  
earnings low:  0. 32   0. 40   1. 35  
revenue high:  516. 50 M 2. 70 B 8. 76 B
revenue avg:  495. 37 M 2. 64 B 8. 62 B
revenue low:  478. 90 M 2. 58 B 8. 45 B
return on assets:  7. 31 % -3. 43 % 4. 51 %
return on equity:  13. 62 % -104. 30 % 140. 44 %
revenue growth:  30. 20 % 295. 25 % 78. 55 %
revenue/share:  9. 38   12. 50   51. 58  

beta (1yr vs S&P500):  1. 17   1. 27   0. 91  
sharpe (1yr):  0. 65   0. 20   0. 80  

held % insiders:  0. 55 % 6. 63 % 3. 46 %
held % institutions:  94. 02 % 76. 45 % 67. 87 %

Research more with google or yahoo!
the data below are updated and re-published at 8pm EDT after each trading day

2019-07-22 : INCY
.    145.491 =       145.491 :: --> INITIAL WEIGHT <--
.    + 1.162 =       146.653 :: earnings per-share addition
.                               --> FUNDAMENTALS <--
.    x 6.139 =       900.247 :: P/E factor
.    x 0.931 =       837.939 :: PE/G factor
.     x 1.68 =       1407.93 :: beta factor
.    x 0.872 =      1228.068 :: sharpe factor
.    x 2.871 =      3525.182 :: current ratio factor
.    x 1.118 =      3940.584 :: quick ratio factor
.    x 1.098 =       4325.53 :: short ratio factor
.    x 1.178 =      5096.996 :: return on assets factor
.    x 1.282 =      6536.158 :: return on equity factor
.    x 1.477 =      9655.914 :: revenue growth factor
.    x 1.127 =     10886.686 :: EV/R factor
.    x 1.095 =     11920.106 :: price-to-book factor
.    x 2.274 =     27103.379 :: EBITDA vs industry factor
.    x 5.553 =    150515.131 :: debt-to-revenue factor
.    x 1.016 =     152974.45 :: debt-to-equity factor
.                               --> PERFORMANCE <--
.    x 2.759 =    422092.429 :: sector+industry 1-year gains factor
.     x 1.01 =    426307.045 :: industry 12-weeks return factor
.    x 1.309 =    558192.153 :: industry 2-weeks return factor
.    x 1.181 =    659102.354 :: company one-year gains+dividend factor
.    x 2.605 =   1717185.497 :: company 13 weeks' performance factor
.    x 1.123 =   1928537.068 :: 5-day avg > 200-day avg
.    x 1.067 =   2057666.773 :: 50-day avg > 200-day avg
.    x 0.987 =   2031508.964 :: "drift" penalty 1 days ago
.    / 1.818 =   1117520.531 :: overall "drift" factor
.    x 0.917 =    1024307.94 :: largest single-day jump factor
.    x 0.994 =   1018046.382 :: volatility factor
.    x 0.994 =   1012143.618 :: 42-day volatility factor
.    x 5.236 =   5299611.766 :: notable returns + performance factor
.    x 3.363 =  17824301.204 :: inverse volume-to-price factor
.                               --> PROJECTIONS <--
.     x 1.29 =  22985990.567 :: forward EPS factor
.    x 1.856 =  42654532.024 :: forward P/E factor
.    x 1.184 =  50501258.891 :: industry recommendation factor
.    x 1.755 =  88647432.742 :: company recommendation factor
.    x 1.002 =  88782118.787 :: factor historical industry gain for week 29
.    x 0.956 =  84899187.162 :: target low factor
.    x 1.093 =  92794570.669 :: target mean factor
.    x 1.026 =  95206347.027 :: target high factor
.    x 4.775 = 454629133.817 :: spline projection factor
.                               --> FINAL ADJUSTMENTS <--
.  quad root =       146.021 :: reduced for readability
.    + 99.95 =       245.971 :: add/subtract for investor sentiment
.   + 23.421 =       269.391 :: earnings report in 8 days
.                               --> FINAL WEIGHT <--
.                    269.391 :: FINAL WEIGHT for NASDAQ:INCY


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org